Johnson & Johnson (NYSE:JNJ) was upgraded by stock analysts at Vetr from a “sell” rating to a “hold” rating in a research report issued on Monday. The firm presently has a $137.71 target price on the stock. Vetr‘s target price would indicate a potential downside of 1.22% from the stock’s current price.
Several other equities analysts have also weighed in on JNJ. Morgan Stanley lifted their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. BidaskClub lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Royal Bank Of Canada reissued a “buy” rating and set a $138.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $145.00 price target (up from $140.00) on shares of Johnson & Johnson in a research report on Friday, July 14th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $143.70.
Shares of Johnson & Johnson (JNJ) opened at 139.41 on Monday. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The firm’s 50-day moving average is $135.68 and its 200-day moving average is $131.64. The stock has a market capitalization of $374.18 billion, a price-to-earnings ratio of 24.25 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.68 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post $7.28 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/01/johnson-johnson-jnj-stock-rating-upgraded-by-vetr-inc.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Country Trust Bank increased its holdings in shares of Johnson & Johnson by 6.2% in the 3rd quarter. Country Trust Bank now owns 354,060 shares of the company’s stock valued at $46,031,000 after acquiring an additional 20,637 shares during the last quarter. Hendershot Investments Inc. increased its holdings in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Hendershot Investments Inc. now owns 38,300 shares of the company’s stock valued at $4,979,000 after acquiring an additional 456 shares during the last quarter. Lincoln National Corp increased its holdings in shares of Johnson & Johnson by 2.6% in the 3rd quarter. Lincoln National Corp now owns 29,757 shares of the company’s stock valued at $3,868,000 after acquiring an additional 758 shares during the last quarter. Verity & Verity LLC increased its holdings in shares of Johnson & Johnson by 1.9% in the 3rd quarter. Verity & Verity LLC now owns 73,090 shares of the company’s stock valued at $9,503,000 after acquiring an additional 1,378 shares during the last quarter. Finally, First Merchants Corp increased its holdings in shares of Johnson & Johnson by 21.0% in the 3rd quarter. First Merchants Corp now owns 55,115 shares of the company’s stock valued at $7,165,000 after acquiring an additional 9,572 shares during the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.